Recent

% | $
Quotes you view appear here for quick access.

Intercept Pharmaceuticals, Inc. Message Board

  • moneyandstocks moneyandstocks Aug 15, 2014 10:45 AM Flag

    The total market for a treatment of NASH is estimated to be over $30 billion. LINK

    Bidness Etc.
    8/14/14
    investors look to capitalize on a potential gold mine
    Intercept has worldwide rights to Obeticholic acid (OCA), which is a multibillion dollar drug if it successfully completes Phase 3 trials for treating Nonalcoholic Steatohepatitis (NASH), for currently there is no treatment for the disease. The total market for a treatment of NASH is estimated to be over $30 billion.

 
ICPT
188.95-0.39(-0.21%)Aug 28 4:00 PMEDT